JNJ-31001074 + paroxetine

JNJ-31001074 + paroxetine refers to the combination of two pharmaceutical agents: **JNJ-31001074 (also known as Bavisant, BEN-2001)** and **paroxetine**. - **JNJ-31001074** is a highly selective, orally active antagonist of the human **histamine H3 receptor**. By blocking this presynaptic autoreceptor, it increases the release of histamine and other neurotransmitters in the brain, which has been investigated for enhancing wakefulness and attention, primarily for **attention deficit hyperactivity disorder (ADHD)** and other conditions like Parkinson’s disease, alcohol dependence, and excessive daytime sleepiness[7][1][2]. - **Paroxetine** is a selective serotonin reuptake inhibitor (SSRI) antidepressant that increases levels of serotonin in the brain, indicated for depression, anxiety disorders, obsessive-compulsive disorder, and other psychiatric conditions[3]. There is no evidence of a fixed-dose combination product or specific clinical evaluation of both drugs co-formulated; this entry describes the simultaneous use of both substances based on the terms provided.